Security
Nkarta, Inc. Common Stock · NKTX
NKTXNASDAQCommon stockCurrentCIK 1787400Updated Oct 6, 2026
NKTX price & chart
Loading TradingView…
NASDAQ:NKTX on TradingView ↗About the company
Nkarta is a clinical-stage biotechnology company advancing the development of allogeneic, off-the-shelf natural killer (NK) cell therapies for people living with autoimmune diseases. By harnessing the power of the innate immune system to eliminate pathogenic B cells driving the autoimmune response, Nkarta is advancing novel cell therapies engineered for deep therapeutic impact. The on-demand availability and outpatient dosing of our CAR-NK cells enables a broad population of patients with different autoimmune conditions to conveniently access NK cell therapy in community health settings. For more information, please visit the company’s website at www.nkartatx.com.
In the news
Nkarta to Present Initial Autoimmune Clinical Data for NKX019 at American College of Rheumatology (ACR) Convergence 2026 ↗
Recent filings
10-Q filing
Results of Operations and Financial Condition
Items 2.02, 9.01
4 filing
Submission of Matters to a Vote of Security Holders
Items 5.07, 9.01
4 filing
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 427,236,000Source | 532,034,000Source | 337,645,000Source | 448,312,000Source | 554,086,000Source | 372,073,000Source | 470,609,000Source | 576,936,000Source | 404,209,000Source | 501,203,000Source | 378,885,000Source | 472,938,000Source |
| Property, Plant and Equipment, NetUSD | 68,182,000Source | 76,231,000Source | 56,768,000Source | 70,341,000Source | 77,551,000Source | 64,417,000Source | 72,625,000Source | 78,522,000Source | 66,721,000Source | 74,658,000Source | 79,326,000Source | 61,908,000Source |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 60,114,000Source | 56,960,000Source | 24,958,000Source | 53,414,000Source | 120,398,000Source | 27,356,000Source | 52,598,000Source | 250,285,000Source | 39,634,000Source | 27,873,000Source | 31,040,000Source | 37,494,000Source |
| Assets, CurrentUSD | 289,275,000Source | 290,150,000Source | 188,045,000Source | 296,571,000Source | 331,799,000Source | 235,885,000Source | 271,551,000Source | 442,781,000Source | 282,512,000Source | 273,338,000Source | 253,071,000Source | 360,688,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 6,944,000Source | 7,095,000Source | 5,281,000Source | 6,884,000Source | 6,978,000Source | 5,457,000Source | 6,044,000Source | 5,387,000Source | 6,233,000Source | 5,984,000Source | 4,882,000Source | 8,545,000Source |
| Operating Lease, Right-of-Use AssetUSD | 33,795,000Source | 38,804,000Source | 30,942,000Source | 35,076,000Source | 39,374,000Source | 33,885,000Source | 35,532,000Source | 39,357,000Source | 34,429,000Source | 36,014,000Source | 39,949,000Source | 45,749,000Source |
| Other Assets, NoncurrentUSD | 1,820,000Source | 4,639,000Source | 1,476,000Source | 1,970,000Source | 3,533,000Source | 1,575,000Source | 4,507,000Source | 3,719,000Source | 1,697,000Source | 4,058,000Source | 3,796,000Source | 1,850,000Source |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 89,336,000Source | 101,161,000Source | 89,907,000Source | 90,644,000Source | 100,902,000Source | 86,213,000Source | 91,804,000Source | 103,285,000Source | 91,884,000Source | 93,227,000Source | 105,600,000Source | 100,731,000Source |
| Stockholders’ equity: | ||||||||||||
| Common Stock, Value, IssuedUSD | 7,000Source | 7,000Source | 7,000Source | 7,000Source | 7,000Source | 7,000Source | 7,000Source | 7,000Source | 7,000Source | 7,000Source | 5,000Source | 5,000Source |
| Retained Earnings (Accumulated Deficit)USD | -620,899,000Source | -518,289,000Source | -716,508,000Source | -599,184,000Source | -489,945,000Source | -676,140,000Source | -576,207,000Source | -464,952,000Source | -648,308,000Source | -544,224,000Source | -435,434,000Source | -317,933,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | 536,000Source | 1,714,000Source | -425,000Source | 362,000Source | -263,000Source | -130,000Source | 652,000Source | -127,000Source | 407,000Source | 674,000Source | 8,000Source | -679,000Source |
| Stockholders' Equity Attributable to ParentUSD | 337,900,000Source | 430,873,000Source | 247,738,000Source | 357,668,000Source | 453,184,000Source | 285,860,000Source | 378,805,000Source | 473,651,000Source | 312,325,000Source | 407,976,000Source | 273,285,000Source | 372,207,000Source |
| Additional Paid in Capital, Common StockUSD | 958,256,000Source | 947,441,000Source | 964,664,000Source | 956,483,000Source | 943,385,000Source | 962,123,000Source | 954,353,000Source | 938,723,000Source | 960,219,000Source | 951,519,000Source | 708,706,000Source | 690,814,000Source |
| Liabilities and EquityUSD | 427,236,000Source | 532,034,000Source | 337,645,000Source | 448,312,000Source | 554,086,000Source | 372,073,000Source | 470,609,000Source | 576,936,000Source | 404,209,000Source | 501,203,000Source | 378,885,000Source | 472,938,000Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 18,988,000Source | 22,468,000Source | 23,561,000Source | 18,927,000Source | 20,861,000Source | 18,207,000Source | 18,756,000Source | 22,189,000Source | 22,266,000Source | 18,917,000Source | 23,330,000Source | 22,046,000Source |
| Operating Lease, Liability, CurrentUSD | 6,373,000Source | 6,756,000Source | 7,280,000Source | 6,912,000Source | 5,532,000Source | 7,081,000Source | 5,950,000Source | 6,078,000Source | 6,889,000Source | 6,050,000Source | 6,069,000Source | 4,249,000Source |
| Accounts Payable, CurrentUSD | 1,437,000Source | 1,937,000Source | 3,819,000Source | 1,510,000Source | 3,764,000Source | 1,586,000Source | 1,490,000Source | 3,177,000Source | 2,089,000Source | 638,000Source | 3,665,000Source | 1,761,000Source |
| Operating Lease, Liability, NoncurrentUSD | 70,261,000Source | 78,693,000Source | 66,259,000Source | 71,630,000Source | 80,041,000Source | 67,919,000Source | 72,961,000Source | 81,096,000Source | 69,531,000Source | 74,223,000Source | 82,270,000Source | 78,685,000Source |
| Other Liabilities, NoncurrentUSD | 87,000Source | — | 87,000Source | 87,000Source | — | 87,000Source | 87,000Source | — | 87,000Source | 87,000Source | — | — |
| Additional Financial Items | ||||||||||||
| Accrued Liabilities, CurrentUSD | 11,178,000Source | 13,775,000Source | 12,462,000Source | 10,505,000Source | 11,565,000Source | 9,540,000Source | 11,316,000Source | 12,934,000Source | 13,288,000Source | 12,229,000Source | 13,596,000Source | 16,036,000Source |
| Short-term InvestmentsUSD | 222,217,000Source | 226,095,000Source | 157,806,000Source | 236,273,000Source | 204,423,000Source | 203,072,000Source | 212,909,000Source | 187,109,000Source | 236,645,000Source | 239,481,000Source | 217,149,000Source | 314,649,000Source |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | — | — | — | — | — | — | -27,832,000Source | -31,983,000Source | -104,084,000Source | -108,790,000Source | -117,501,000Source | -113,837,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Depreciation, Depletion and AmortizationUSD | — | — | 2,300,000Source | 2,400,000Source | 2,700,000Source | 2,300,000Source | 2,300,000Source | 2,300,000Source | 9,200,000Source | 9,200,000Source | 5,900,000Source | 2,600,000Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | 1,773,000Source | 4,055,000Source | 1,865,000Source | 2,053,000Source | 1,898,000Source | 2,834,000Source | 8,559,000Source | 16,731,000Source | 17,199,000Source | 16,856,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | -28,199,000Source | -29,612,000Source | -88,699,000Source | -99,696,000Source | -86,160,000Source | -57,000,000Source |
| Cash flows from investing activities: | ||||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | 15,915,000Source | 54,337,000Source | 100,319,000Source | -129,555,000Source | 79,015,000Source | -184,689,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | — | — | — | — | 413,000Source | 518,000Source | 1,208,000Source | 4,409,000Source | 28,147,000Source | 47,111,000Source |
| Cash flows from financing activities: | ||||||||||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | 6,000Source | 0Source | 141,000Source | 226,084,000Source | 691,000Source | 219,012,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | — | — | — | -12,278,000Source | 24,725,000Source | 11,761,000Source | -3,167,000Source | -6,454,000Source | -22,677,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | 62,857,000Source | 59,703,000Source | 27,701,000Source | 56,157,000Source | 30,099,000Source | 55,341,000Source | 42,377,000Source | 30,616,000Source | 33,783,000Source | 40,237,000Source |
| Additional Financial Items | ||||||||||||
| Share-based Payment Arrangement, ExpenseUSD | — | — | 1,773,000Source | 4,055,000Source | 1,865,000Source | 2,053,000Source | 1,898,000Source | 2,834,000Source | 8,559,000Source | 16,731,000Source | 17,199,000Source | 16,856,000Source |
| Debt Securities, Available-for-sale, Realized Gain (Loss)USD | — | — | — | — | — | — | — | 0Source | 94,000Source | — | 34,000Source | -490,000Source |
| General and Administrative ExpenseUSD | — | — | 7,088,000Source | 8,544,000Source | 14,082,000Source | 6,408,000Source | 5,888,000Source | 12,392,000Source | 31,568,000Source | 31,450,000Source | 34,877,000Source | 28,058,000Source |
| Income Tax Expense (Benefit)USD | — | — | 0Source | 0Source | — | — | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -21,715,000Source | -28,344,000Source | -40,368,000Source | -22,977,000Source | -27,832,000Source | -31,983,000Source | -104,084,000Source | -108,790,000Source | -117,501,000Source | -113,837,000Source |
| Nonoperating Income (Expense)USD | — | — | 5,571,000Source | 5,450,000Source | 2,760,000Source | 4,209,000Source | 3,044,000Source | 4,581,000Source | 17,913,000Source | 19,404,000Source | 14,149,000Source | 5,118,000Source |
| Operating ExpensesUSD | — | — | 27,286,000Source | 33,794,000Source | 43,128,000Source | 27,186,000Source | 30,876,000Source | 36,564,000Source | 121,997,000Source | 128,194,000Source | 131,650,000Source | 118,955,000Source |
| Operating Lease, Impairment LossUSD | — | — | 791,000Source | 0Source | 2,378,000Source | 0Source | — | — | 791,000Source | 0Source | 4,100,000Source | — |
| Other Nonoperating Income (Expense)USD | — | — | 1,719,000Source | -3,000Source | 222,000Source | 239,000Source | 206,000Source | 205,000Source | 2,419,000Source | 87,000Source | 42,000Source | -470,000Source |
| Payments to Acquire InvestmentsUSD | — | — | — | — | — | — | 54,277,000Source | 20,581,000Source | 238,565,000Source | 406,376,000Source | 260,233,000Source | — |
| Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-saleUSD | — | — | — | — | — | — | — | — | — | — | — | 248,309,000Source |
| Proceeds from Stock Options ExercisedUSD | — | — | — | — | — | — | 6,000Source | 0Source | 0Source | 668,000Source | 161,000Source | 1,397,000Source |
| Unrealized Gain (Loss) on InvestmentsUSD | — | — | 174,000Source | 1,977,000Source | -295,000Source | -290,000Source | -537,000Source | -22,000Source | -267,000Source | 666,000Source | 687,000Source | — |
| Operating Lease, Expense | — | — | —Source | —Source | —Source | —Source | —Source | —Source | — | — | — | — |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total RevenueUSD | — | — | — | — | — | — | — | — | 0Source | 0Source | — | — |
| Operating Income (Loss)USD | — | — | -27,286,000Source | -33,794,000Source | -43,128,000Source | -27,186,000Source | -30,876,000Source | -36,564,000Source | -121,997,000Source | -128,194,000Source | -131,650,000Source | -118,955,000Source |
| Other Nonoperating Income (Expense)USD | — | — | 1,719,000Source | -3,000Source | 222,000Source | 239,000Source | 206,000Source | 205,000Source | 2,419,000Source | 87,000Source | 42,000Source | -470,000Source |
| Income Tax Expense (Benefit)USD | — | — | 0Source | 0Source | — | — | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -21,715,000Source | -28,344,000Source | -40,368,000Source | -22,977,000Source | -27,832,000Source | -31,983,000Source | -104,084,000Source | -108,790,000Source | -117,501,000Source | -113,837,000Source |
| Earnings Per Share, BasicUSD per share | — | — | -0.29Source | -0.39Source | -0.54Source | -0.31Source | -0.37Source | -0.43Source | -1.41Source | -1.6Source | -2.4Source | -2.61Source |
| Earnings Per Share, DilutedUSD per share | — | — | -0.29Source | -0.39Source | -0.54Source | -0.31Source | -0.37Source | -0.43Source | -1.41Source | -1.6Source | -2.4Source | -2.61Source |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 74,024,543Source | 73,563,316Source | 74,494,855Source | 73,977,625Source | 74,257,973Source | 73,916,477Source | 73,991,197Source | 67,865,323Source | 49,014,300Source | 43,631,722Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 74,024,543Source | 73,563,316Source | 74,494,855Source | 73,977,625Source | 74,257,973Source | 73,916,477Source | 73,991,197Source | 67,865,323Source | 49,014,300Source | 43,631,722Source |
| Additional Financial Items | ||||||||||||
| Common Stock, Dividends, Per Share, DeclaredUSD per share | — | — | — | — | — | — | — | — | 0Source | 0Source | — | — |
| Depreciation, Depletion and Amortization, NonproductionUSD | — | — | 2,306,000Source | 2,347,000Source | 2,732,000Source | 2,331,000Source | 2,340,000Source | 2,299,000Source | 9,193,000Source | 9,152,000Source | 5,869,000Source | 2,637,000Source |
| General and Administrative ExpenseUSD | — | — | 7,088,000Source | 8,544,000Source | 14,082,000Source | 6,408,000Source | 5,888,000Source | 12,392,000Source | 31,568,000Source | 31,450,000Source | 34,877,000Source | 28,058,000Source |
| Investment Income, NetUSD | — | — | 3,852,000Source | 5,453,000Source | 2,538,000Source | 3,970,000Source | 2,838,000Source | 4,376,000Source | 15,494,000Source | 19,317,000Source | 14,107,000Source | 5,588,000Source |
| Nonoperating Income (Expense)USD | — | — | 5,571,000Source | 5,450,000Source | 2,760,000Source | 4,209,000Source | 3,044,000Source | 4,581,000Source | 17,913,000Source | 19,404,000Source | 14,149,000Source | 5,118,000Source |
| Operating ExpensesUSD | — | — | 27,286,000Source | 33,794,000Source | 43,128,000Source | 27,186,000Source | 30,876,000Source | 36,564,000Source | 121,997,000Source | 128,194,000Source | 131,650,000Source | 118,955,000Source |
| Research and Development ExpenseUSD | — | — | 20,198,000Source | 25,250,000Source | 29,046,000Source | 20,778,000Source | 24,988,000Source | 24,172,000Source | 90,429,000Source | 96,744,000Source | 96,773,000Source | 90,897,000Source |
| Operating Lease, Expense | — | — | —Source | —Source | —Source | —Source | —Source | —Source | — | — | — | — |
Filing attachments
nktx-ex99_1.htm · 8-K · 2026-08-10
EX-99.1 2 nktx-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Nkarta Reports Second Quarter 2026 Financial Results and Corporate Highlights • Enrollment continues across all indications in Ntrust-1 and Ntrust-2 at the 4 billion cell dose level (12 billion cells in 3-dose cycle) • Initial clinical data from Ntrust-1 and Ntrust-2 expected to be presented at a medical conference in 2026 • Cash balance of $243.2 million on June 30, 2026, including cash, cash equivalents and investments, expected t…
Read attachment ↗nktx-ex99_1.htm · 8-K · 2026-05-12
EX-99.1 2 nktx-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Nkarta Reports First Quarter 2026 Financial Results and Corporate Highlights • Enrollment ongoing at 4 billion cell dose level (12 billion cells in 3-dose cycle) across all indications in Ntrust-1 and Ntrust-2 • Regulatory agreement supports expansion into community-based settings with outpatient dosing to reduce patient burden • Initial clinical data from Ntrust-1 and Ntrust-2 expected to be presented at a medical meeting in 2026 …
Read attachment ↗nktx-ex99_1.htm · 8-K · 2026-03-25
EX-99.1 2 nktx-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Nkarta Reports Fourth Quarter and Full Year 2025 Financial Results and Corporate Highlights • Dose escalation for NKX019 advanced to 4 billion cells per dose on days 0, 3 and 7 for a total of 12 billion cells per cycle • Initial clinical data from Ntrust-1 and Ntrust-2 targeted for presentation at a medical conference in 2026 • Cash balance of $295.1 million on December 31, 2025, including cash, cash equivalents and investments, is …
Read attachment ↗